| Year |
Citation |
Score |
| 2021 |
Bryant CM, Henderson RH, Nichols RC, Mendenhall WM, Hoppe BS, Vargas CE, Daniels TB, Choo CR, Parikh RR, Giap H, Slater JD, Vapiwala N, Barrett W, Nanda A, Mishra MV, et al. Consensus Statement on Proton Therapy for Prostate Cancer. International Journal of Particle Therapy. 8: 1-16. PMID 34722807 DOI: 10.14338/IJPT-20-00031.1 |
0.305 |
|
| 2015 |
Braunstein LZ, Chen MH, Dosoretz DE, Salenius SA, Katin MJ, Nanda A, D'Amico AV. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk. Clinical Genitourinary Cancer. PMID 26003267 DOI: 10.1016/J.Clgc.2015.04.010 |
0.448 |
|
| 2015 |
Braunstein LZ, Chen M, Dosoretz DE, Salenius S, Katin M, Nanda A, D'Amico AV. Abstract 3438: Whole pelvis versus prostate-only radiotherapy with or without short course androgen deprivation therapy and mortality risk Cancer Research. 75: 3438-3438. DOI: 10.1158/1538-7445.Am2015-3438 |
0.435 |
|
| 2015 |
Braunstein L, Chen M, Dosoretz D, Salenius S, Katin M, Nanda A, D'Amico A. Whole-Pelvis Versus Prostate-Only Radiation Therapy and Androgen Deprivation Therapy: Effects on Mortality Risk International Journal of Radiation Oncology*Biology*Physics. 93: E190-E191. DOI: 10.1016/J.IJROBP.2015.07.1035 |
0.338 |
|
| 2014 |
Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 89: 509-17. PMID 24929162 DOI: 10.1016/j.ijrobp.2014.03.012 |
0.304 |
|
| 2014 |
Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. European Urology. 65: 177-85. PMID 22981136 DOI: 10.1016/J.Eururo.2012.08.070 |
0.403 |
|
| 2013 |
Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. International Journal of Radiation Oncology, Biology, Physics. 85: e209-15. PMID 23332383 DOI: 10.1016/J.Ijrobp.2012.11.039 |
0.449 |
|
| 2013 |
Kim D, Straka C, Cho L, Xie X, Lotan Y, Kavanagh BD, Pistenmaa DA, Kupelian P, Nanda A, Timmerman RD. Predictors of High-Grade Rectal Toxicity Observed in a Phase 1/2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.941 |
0.421 |
|
| 2010 |
Nanda A, D'Amico AV. Hormonal therapy and radiation for prostate cancer: is it safe? Expert Review of Anticancer Therapy. 10: 979-81. PMID 20645684 DOI: 10.1586/Era.10.83 |
0.435 |
|
| 2010 |
Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 77: 147-52. PMID 19744800 DOI: 10.1016/J.Ijrobp.2009.04.085 |
0.457 |
|
| 2010 |
Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 76: 1439-44. PMID 19540066 DOI: 10.1016/J.Ijrobp.2009.03.034 |
0.436 |
|
| 2010 |
Nanda A, Chen M, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Whole Pelvis vs. Prostate Only Irradiation and Mortality in Men with Prostate Cancer Treated with or without Hormonal Therapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.1320 |
0.455 |
|
| 2009 |
Nanda A, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with radiation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9543. PMID 27963605 DOI: 10.1200/Jco.2009.27.15_Suppl.9543 |
0.472 |
|
| 2009 |
Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. Jama. 302: 866-73. PMID 19706860 DOI: 10.1001/Jama.2009.1137 |
0.392 |
|
| 2009 |
Nanda A, Chen MH, D'Amico AV. Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1728-9; author reply. PMID 19237624 DOI: 10.1200/Jco.2008.21.5392 |
0.413 |
|
| 2009 |
Nanda A, Chen MH, Renshaw AA, D'Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. International Journal of Radiation Oncology, Biology, Physics. 74: 1419-23. PMID 19131185 DOI: 10.1016/J.Ijrobp.2008.10.027 |
0.436 |
|
| 2009 |
Nanda A, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. Cardiac Comorbidity and Mortality in Men with Prostate Cancer Treated with Brachytherapy with or without Neoadjuvant Hormonal Therapy International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.218 |
0.434 |
|
| 2008 |
Nanda A, Dias-Santagata DC, Stubbs H, O'Hara CJ, Zaner KS, Lynch TJ, Willers H. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clinical Lung Cancer. 9: 285-7. PMID 18824451 DOI: 10.3816/Clc.2008.N.044 |
0.362 |
|
| 2008 |
Nanda A, D'Amico AV. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials. Bju International. 102: 1366-8. PMID 18778343 DOI: 10.1111/J.1464-410X.2008.08027.X |
0.425 |
|
| 2008 |
Nanda A, Chen M, Renshaw AA, D'Amico AV. PSA Recurrence in Men Following Definitive Therapy for Prostate Cancer with Gleason Score 9/10, 8, and 7 with Tertiary Grade 5 Disease International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.856 |
0.446 |
|
| 2006 |
Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, Croix BS, Kinzler KW, Huso DL. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors Proceedings of the National Academy of Sciences of the United States of America. 103: 3351-3356. PMID 16492758 DOI: 10.1073/Pnas.0511306103 |
0.466 |
|
| 2004 |
Nanda A, Buckhaults P, Seaman S, Agrawal N, Boutin P, Shankara S, Nacht M, Teicher B, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B. Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R. Cancer Research. 64: 8507-11. PMID 15574754 DOI: 10.1158/0008-5472.Can-04-2716 |
0.419 |
|
| 2004 |
Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Research. 64: 817-20. PMID 14871805 DOI: 10.1158/0008-5472.Can-03-2408 |
0.447 |
|
| 2004 |
Nanda A, St Croix B. Tumor endothelial markers: new targets for cancer therapy. Current Opinion in Oncology. 16: 44-9. PMID 14685092 DOI: 10.1097/00001622-200401000-00009 |
0.361 |
|
| 2001 |
Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Research. 61: 6649-55. PMID 11559528 |
0.443 |
|
| Show low-probability matches. |